Quarterly ResultMay 12, 2026, 04:03 PM
Nkarta Q1 Net Loss $27.8M; NKX019 Outpatient Dosing Approved
AI Summary
Nkarta reported a net loss of $27.8 million for the first quarter of 2026. The company announced a significant regulatory agreement with the FDA to amend its protocol, allowing outpatient dosing in community settings for its NKX019 clinical trials (Ntrust-1 and Ntrust-2), along with re-dosing options and the removal of overnight monitoring. Enrollment is ongoing at the 4 billion cell dose level across all indications, and initial clinical data is expected to be presented at a medical meeting in 2026. Nkarta's cash balance of $266.7 million as of March 31, 2026, is projected to fund operations into 2029.
Key Highlights
- Regulatory agreement with FDA allows outpatient dosing and re-dosing for NKX019 trials.
- Ntrust-2 study expanded to include patients with rheumatoid arthritis.
- Enrollment continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) for Ntrust-1 and Ntrust-2.
- Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026.
- Cash, cash equivalents, and investments totaled $266.7 million as of March 31, 2026.
- Cash balance expected to fund operations into 2029.
- Net loss for Q1 2026 was $27.8 million, or $0.37 per basic and diluted share.
- Research and development (R&D) expenses were $25.0 million for Q1 2026.